Thomas Baldwin, MD
Interventional Cardiology · Olathe, KSNPI 1104872746
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $4,411 of the $6,451 with a category attached, or 68.4%. 34 manufacturers reported payments, led by Medtronic at 45.8% of the total. Reporting peaked in 2022 at $3,274 and has fallen 88.0% since, to $393 in 2025. That places this record below the midpoint for interventional cardiology clinicians in KS, where the typical reported total is $8,846.
Across 231 payments — averaging $27.93 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$3K
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$339
- Amgen$307
- Pfizer$264
- Boston Scientific$257
- Irhythm Technologies, Inc.$246
- plus $2K from 28 others
What the payments were for
- Grants$551%
- Travel & lodging$1,95330%
- Food & beverage$4,41168%
- Education$321%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic(2 entities) | 35 | $2,955 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 22 | $339 |
| Amgen | 20 | $307 |
| Pfizer | 16 | $264 |
| Boston Scientific | 12 | $257 |
| Irhythm Technologies, Inc. | 11 | $246 |
| Novo Nordisk | 10 | $220 |
| E.r. Squibb & Sons, L.L.C. | 12 | $202 |
| Boehringer Ingelheim | 13 | $200 |
| Johnson & Johnson | 13 | $191 |
| Sanofi-aventis U.S. LLC | 12 | $189 |
| Novartis | 10 | $137 |
| AstraZeneca | 7 | $116 |
| Kestra Medical Technology Services, Inc. | 5 | $112 |
| Abbott | 5 | $110 |
| Cook Medical LLC | 1 | $89 |
| Shockwave Medical, Inc | 1 | $86 |
| Regeneron Healthcare Solutions, Inc. | 5 | $77 |
| Alnylam Pharmaceuticals Inc. | 4 | $62 |
| Kiniksa Pharmaceuticals International, PLC | 2 | $31 |
| Teleflex LLC | 2 | $31 |
| Recor Medical Inc | 1 | $29 |
| Cardiva Medical, Inc. | 1 | $24 |
| Actelion Pharmaceuticals US, Inc. | 1 | $23 |
| Sanofi | 1 | $20 |
| Vital Connect, Inc | 1 | $20 |
| Kiniksa Pharmaceuticals, Ltd. | 1 | $17 |
| Philips North America LLC | 1 | $15 |
| Esperion Therapeutics, Inc. | 1 | $15 |
| Biocompatibles, Inc. | 1 | $15 |
| Bayer | 1 | $14 |
| Heartflow, Inc. | 1 | $14 |
| Scpharmaceuticals Inc. | 1 | $13 |
| Cvrx, Inc. | 1 | $10 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- RESOLUTE ONYX$1,779
- Micra$201
- Resolute$129
How this compares
$6,451 in reported general payments places this provider in the 40th percentile of 55 interventional cardiology providers in Kansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 109 | $114,427 |
| EntrestoSacubitril/Valsartan | 60 | $81,783 |
| JardianceEmpagliflozin | 48 | $61,645 |
| Repatha SureclickEvolocumab | 27 | $35,966 |
| XareltoRivaroxaban | 17 | $20,027 |
| WegovySemaglutide | 12 | $19,980 |
| FarxigaDapagliflozin Propanediol | 16 | $13,886 |
| Atorvastatin Calcium | 354 | $4,058 |
| ClopidogrelClopidogrel Bisulfate | 215 | $2,725 |
| Ezetimibe | 73 | $2,360 |
| Losartan Potassium | 183 | $1,483 |
| Metoprolol Succinate | 110 | $1,411 |
| Rosuvastatin Calcium | 147 | $1,373 |
| Carvedilol | 116 | $1,289 |
| Bisoprolol Fumarate | 65 | $1,260 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $264 | $114,427109 claims |
| NovartisEntresto | $137 | $81,78360 claims |
| Boehringer IngelheimJardiance | $200 | $61,64548 claims |
| Johnson & JohnsonXarelto | $191 | $20,02717 claims |
| Novo NordiskWegovy | $220 | $19,98012 claims |
| AstraZenecaFarxiga | $116 | $13,88616 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 55 interventional cardiology providers in Kansas.
Other interventional cardiology in Olathe
- Brian FriedmanOlathe$5K
- Anthony SpaedyKansas City$385K
- Prasad GunasekaranKansas City$76K
- Maheedhar GedelaWichita$54K
- Kamal GuptaKansas City$46K
- Priyantha RanaweeraManhattan$41K
- Mark WileyKansas City$39K
- Ahmed SoukaTopeka$37K
- Pouyan ArmanOverland Park$33K
- John SerfasKansas City$31K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.